After participating, you will be able to:


  • Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.
  • Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.
  • Describe currently available molecular tests for breast tumors and the implications of these results for managing treatment-resistant breast cancer.